drugset
drugset / Trial / NCT00003167

Gene Therapy in Treating Patients With Advanced Bladder Cancer

NCT00003167 ↗

Phase 1 Completed 24 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer

Timeline

Start
1998-05
Primary completion
2002-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject CONTUSUGENE LADENOVEC Unknown — Other

Indications

bladder transitional cell carcinoma